Literature DB >> 10499354

The involvement of the NMDA receptor complex in the protective effect of anticholinergic drugs against soman poisoning.

L Raveh1, S Chapman, G Cohen, D Alkalay, E Gilat, I Rabinovitz, B A Weissman.   

Abstract

Organophosphate poisoning is associated with adverse effects on the central nervous system such as seizure/convulsive activity and long term changes in neuronal networks. This study reports on investigations designed to assess the consequences of soman exposure on excitatory amino acids receptors in the rat brain. In addition, the protective effects of caramiphen which acts at these receptors, and scopolamine, which does not, was determined on soman-induced alteration in rat brain functions. Administration of soman (1xLD50) to pyridostigmine pretreated rats produced seizure activity (measured by EEG monitoring) in all animals tested. Estimation of [3H]MK-801 binding to brain membranes from intoxicated rats revealed a marked decrease in Bmax value 24 but not 2 hrs following soman administration. The specific nature of these effects of soman was demonstrated by the findings that [3H]flunitrazepam binding to central benzodiazepine receptors remained unchanged in soman-poisoned rat brain membranes. Both scopolamine and caramiphen, when used prophylactically prevented the lethal effect of soman and completely blocked the development of electrographic seizure activity (EGSA). In contrast, only caramiphen abolished soman-induced modifications in NMDA/ion channel characteristics. Caramiphen displaced [3H]MK-801 bound to the NMDA/ion channel complex, possibly by interacting with the Zn2+ site whereas scopolamine did not. Moreover, caramiphen, but not scopolamine, partially protected mice from NMDA-induced lethality. Thus, it is suggested that an important component of the protective efficacy of caramiphen against organophosphate poisoning might be attributed to its ability to modulate NMDA receptors in addition to its anticholinergic properties.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499354

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  7 in total

1.  Neuroprotective efficacy of caramiphen against soman and mechanisms of its action.

Authors:  T H Figueiredo; V Aroniadou-Anderjaska; F Qashu; J P Apland; V Pidoplichko; D Stevens; T M Ferrara; M F M Braga
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

2.  Alpha-Linolenic Acid-Induced Increase in Neurogenesis is a Key Factor in the Improvement in the Passive Avoidance Task After Soman Exposure.

Authors:  Tetsade C B Piermartiri; Hongna Pan; Jun Chen; John McDonough; Neil Grunberg; James P Apland; Ann M Marini
Journal:  Neuromolecular Med       Date:  2015-04-29       Impact factor: 3.843

3.  Comparing the Antiseizure and Neuroprotective Efficacy of LY293558, Diazepam, Caramiphen, and LY293558-Caramiphen Combination against Soman in a Rat Model Relevant to the Pediatric Population.

Authors:  James P Apland; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Volodymyr I Pidoplichko; Katia Rossetti; Maria F M Braga
Journal:  J Pharmacol Exp Ther       Date:  2018-02-21       Impact factor: 4.030

Review 4.  Acute and long-term consequences of exposure to organophosphate nerve agents in humans.

Authors:  Taiza H Figueiredo; James P Apland; Maria F M Braga; Ann M Marini
Journal:  Epilepsia       Date:  2018-08-29       Impact factor: 5.864

5.  Anticonvulsant efficacy of drugs with cholinergic and/or glutamatergic antagonism microinfused into area tempestas of rats exposed to soman.

Authors:  Trond Myhrer; Siri Enger; Pål Aas
Journal:  Neurochem Res       Date:  2007-08-21       Impact factor: 3.996

6.  Full Protection Against Soman-Induced Seizures and Brain Damage by LY293558 and Caramiphen Combination Treatment in Adult Rats.

Authors:  James P Apland; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Marcio De Araujo Furtado; Maria F M Braga
Journal:  Neurotox Res       Date:  2018-04-30       Impact factor: 3.911

7.  Organophosphate intermediate syndrome with neurological complications of extrapyramidal symptoms in clinical practice.

Authors:  Mark B Detweiler
Journal:  J Neurosci Rural Pract       Date:  2014-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.